Doctors successfully treated a 61-year-old woman with advanced pancreatic cancer by removing her entire pancreas and reconstructing two major blood vessels, allowing her to survive 27 months without cancer returning to the original site. This case demonstrates that complex vascular reconstruction during pancreatic cancer surgery is technically feasible in carefully selected patients who respond well to chemotherapy.
A 61-year-old woman with advanced pancreatic cancer that had grown into major blood vessels received an aggressive treatment combining strong chemotherapy drugs followed by extensive surgery. Doctors removed her entire pancreas, spleen, and portions of two critical blood vessels, then reconstructed them to restore blood flow to her liver. According to Gram Research analysis, this complex case demonstrates how modern surgical techniques can treat pancreatic cancer even when it involves vital blood vessels. The patient survived 27 months after surgery without the cancer returning to its original location, showing that aggressive treatment can extend survival in carefully selected patients.
Key Statistics
A 2026 case report documented a 61-year-old woman with locally advanced pancreatic cancer involving major blood vessels who survived 27 months after undergoing total pancreatectomy with portal vein and hepatic artery resection and reconstruction.
In this case, the patient received 12 cycles of FOLFIRINOX chemotherapy before surgery, resulting in a 1.3-centimeter tumor with only 2 of 41 lymph nodes involved and negative surgical margins at final pathology.
The patient remained free of cancer recurrence at the original tumor site for 27 months following aggressive surgical reconstruction, though ultimately died from pneumonia rather than pancreatic cancer progression.
The Quick Take
- What they studied: How doctors can surgically treat pancreatic cancer when the tumor has grown into major blood vessels that supply the liver and other organs.
- Who participated: One 61-year-old woman with locally advanced pancreatic cancer that had invaded the portal vein and hepatic artery, two critical blood vessels.
- Key finding: The patient survived 27 months after surgery without cancer returning to the original site, demonstrating that complex vascular reconstruction during pancreatic cancer surgery is technically feasible and may extend survival in selected cases.
- What it means for you: This case shows that some patients with advanced pancreatic cancer involving blood vessels may benefit from aggressive combined treatment, though outcomes vary significantly and this approach is only suitable for carefully selected patients in good health.
The Research Details
This is a case report, which means doctors documented the detailed medical story of one patient to illustrate an unusual or instructive clinical situation. The patient presented with jaundice (yellowing of skin and eyes) and elevated tumor markers, leading to a diagnosis of pancreatic adenocarcinoma, a common and aggressive form of pancreatic cancer. Imaging showed the tumor had invaded two major blood vessels: the portal vein (which carries nutrient-rich blood to the liver) and the common hepatic artery (which delivers oxygen-rich blood to the liver). Before surgery, the patient received 12 cycles of FOLFIRINOX, a combination of four chemotherapy drugs designed to shrink the tumor and kill cancer cells throughout the body.
Case reports are valuable for documenting rare surgical techniques and complex patient management. They help surgeons learn what is technically possible and provide detailed information about outcomes that cannot be captured in larger studies. This case is important because it demonstrates that removing and reconstructing major blood vessels during pancreatic cancer surgery is feasible, which expands treatment options for patients who would otherwise have no surgical option.
As a single case report, this study has significant limitations. It describes one patient’s experience and cannot prove that this approach works for all patients with similar cancers. Case reports are the lowest level of scientific evidence. However, the detailed surgical documentation and 27-month follow-up provide valuable technical and clinical information for surgeons considering similar procedures. The fact that the patient had no cancer recurrence at the original site suggests the aggressive approach may have benefit, though longer follow-up and comparison with other patients would be needed to draw firm conclusions.
What the Results Show
The surgical team successfully removed the entire pancreas, spleen, a 4-centimeter segment of the portal vein, and the common hepatic artery. They then reconstructed the portal vein by connecting the cut ends directly together, and restored blood flow to the liver by moving the splenic artery (which normally supplies the spleen) to connect to the hepatic artery. The final pathology showed a 1.3-centimeter tumor with moderate differentiation, meaning the cancer cells looked somewhat abnormal but not extremely aggressive. Only 2 of 41 lymph nodes contained cancer, and the surgical margins were negative, meaning no cancer cells were found at the edges of the removed tissue. This is an important indicator of complete tumor removal. After surgery, the patient developed a chylous fistula (an abnormal connection leaking lymphatic fluid), which was managed with drainage and intravenous nutrition until it healed. The patient remained free of cancer at the original site for 27 months, when a single metastasis (spread) appeared in the lung and was surgically removed.
The patient’s initial CA 19-9 tumor marker level was 210 U/mL, which is elevated (normal is below 37). The chemotherapy and surgery successfully controlled the cancer locally, as evidenced by the absence of locoregional recurrence throughout the follow-up period. The patient ultimately died 27 months after the initial surgery from severe pneumonia, not from pancreatic cancer progression. This suggests the aggressive surgical approach did not compromise the patient’s ability to survive long-term, though the ultimate outcome was limited by infection rather than cancer.
Pancreatic cancer involving major blood vessels is typically considered unresectable, meaning surgeons traditionally would not attempt removal because the risks were thought to outweigh benefits. In recent years, advances in surgical technique and patient selection have made vascular resection and reconstruction during pancreatic cancer surgery more common. This case adds to the growing literature showing that selected patients with locally advanced pancreatic cancer can undergo complex vascular reconstruction. However, most patients with pancreatic cancer still have poor outcomes, and this case represents a favorable scenario with good response to chemotherapy and successful surgery.
This is a single case report, so the findings cannot be generalized to other patients. The patient was carefully selected and had several favorable factors: good response to chemotherapy, no distant metastases at the time of surgery, and good overall health. Results may be very different in patients without these advantages. The 27-month survival is longer than typical for pancreatic cancer, but this patient ultimately died from pneumonia rather than cancer progression, so we cannot know how much longer survival would have been without the infection. Without a comparison group of similar patients treated differently, we cannot determine whether the aggressive surgical approach actually improved survival compared to other treatments. Long-term follow-up data from multiple patients would be needed to establish whether this approach should become standard practice.
The Bottom Line
This case demonstrates that complex vascular reconstruction during pancreatic cancer surgery is technically possible in highly selected patients. However, this aggressive approach should only be considered for patients with locally advanced pancreatic cancer (no distant spread) who have responded well to chemotherapy and are in excellent overall health. Patients should discuss with their surgical team whether they are candidates for this procedure. Moderate confidence: This recommendation is based on a single case and should be considered alongside other treatment options and the patient’s individual circumstances.
This information is most relevant for patients with locally advanced pancreatic cancer involving blood vessels, their families, and their medical teams. Patients with metastatic pancreatic cancer (cancer that has spread to distant organs) would not be candidates for this approach. Patients in poor health or with significant comorbidities may not tolerate such extensive surgery. Surgeons specializing in pancreatic cancer at major medical centers should be aware of these techniques for appropriate patient selection.
In this case, the patient received 12 cycles of chemotherapy before surgery, which typically takes 3 to 4 months. Recovery from this extensive surgery takes several months, with gradual return to normal activities over 6 to 12 months. The patient in this case survived 27 months after surgery before dying from an unrelated infection, though this is longer than the typical survival for pancreatic cancer.
Frequently Asked Questions
Can pancreatic cancer that involves blood vessels be surgically removed?
Yes, in carefully selected patients. This case shows that surgeons can remove pancreatic cancer involving major blood vessels and reconstruct those vessels to restore blood flow. However, this approach is only appropriate for patients without distant metastases who respond well to chemotherapy and are in excellent health.
What is FOLFIRINOX and why is it used for pancreatic cancer?
FOLFIRINOX is a combination of four chemotherapy drugs (leucovorin, fluorouracil, irinotecan, and oxaliplatin) that work together to kill cancer cells. It is used before surgery to shrink tumors and eliminate cancer cells, improving the chances that surgery can completely remove all cancer.
How long do pancreatic cancer patients typically survive after surgery?
Survival varies widely depending on cancer stage and individual factors. This patient survived 27 months after surgery, which is longer than average for pancreatic cancer. Most patients with pancreatic cancer have shorter survival times, but aggressive treatment in selected cases may extend survival.
What happens when surgeons remove blood vessels during cancer surgery?
Surgeons remove the affected blood vessel segment along with the cancer, then reconnect the healthy ends or use other blood vessels to restore blood flow. In this case, doctors moved the splenic artery to replace the hepatic artery, ensuring the liver continued receiving blood.
Is this aggressive pancreatic cancer surgery right for all patients?
No. This approach is only suitable for patients with locally advanced cancer (no distant spread), good response to chemotherapy, and excellent overall health. Patients with metastatic disease or significant health problems would not be candidates and might benefit from other treatment approaches.
Want to Apply This Research?
- For patients undergoing pancreatic cancer treatment, track weekly CA 19-9 tumor marker levels (if monitored by your doctor), chemotherapy cycle completion dates, and major surgery dates. Monitor for complications like infection, fluid drainage, and changes in digestion or energy levels.
- If you are a pancreatic cancer patient considering aggressive treatment, use the app to maintain a detailed symptom diary including pain, jaundice, appetite, and energy levels. Share this with your medical team to help them assess your response to treatment and adjust your care plan accordingly.
- Long-term tracking should include imaging scan results (CT or MRI), tumor marker levels, weight changes, and any signs of cancer recurrence or new symptoms. Set reminders for follow-up appointments and imaging studies as recommended by your oncology team, typically every 3 to 6 months initially.
This case report describes one patient’s experience and should not be considered a recommendation for all pancreatic cancer patients. Treatment decisions for pancreatic cancer must be individualized based on cancer stage, extent of vascular involvement, response to chemotherapy, overall health status, and patient preferences. Patients should discuss all available treatment options, including surgery, chemotherapy, radiation, and supportive care, with their oncology and surgical teams. This information is for educational purposes and does not replace professional medical advice. Outcomes vary significantly between patients, and aggressive surgical approaches carry substantial risks that must be carefully weighed against potential benefits.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.